Annual EBITDA
-$3.76 B
-$473.00 M-14.41%
December 31, 2024
Summary
- As of February 20, 2025, MRNA annual EBITDA is -$3.76 billion, with the most recent change of -$473.00 million (-14.41%) on December 31, 2024.
- During the last 3 years, MRNA annual EBITDA has fallen by -$17.28 billion (-127.76%).
- MRNA annual EBITDA is now -127.76% below its all-time high of $13.53 billion, reached on December 31, 2021.
Performance
MRNA EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$1.19 B
-$1.26 B-1601.27%
December 31, 2024
Summary
- As of February 20, 2025, MRNA quarterly EBITDA is -$1.19 billion, with the most recent change of -$1.26 billion (-1601.27%) on December 31, 2024.
- Over the past year, MRNA quarterly EBITDA has dropped by -$1.46 billion (-526.62%).
- MRNA quarterly EBITDA is now -121.61% below its all-time high of $5.49 billion, reached on December 31, 2021.
Performance
MRNA Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$3.46 B
-$1.46 B-73.27%
December 31, 2024
Summary
- As of February 20, 2025, MRNA TTM EBITDA is -$3.46 billion, with the most recent change of -$1.46 billion (-73.27%) on December 31, 2024.
- Over the past year, MRNA TTM EBITDA has dropped by -$179.00 million (-5.45%).
- MRNA TTM EBITDA is now -120.90% below its all-time high of $16.56 billion, reached on March 31, 2022.
Performance
MRNA TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
MRNA EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -14.4% | -526.6% | -5.5% |
| 3 y3 years | -127.8% | -526.6% | -5.5% |
| 5 y5 years | -629.3% | -526.6% | -5.5% |
MRNA EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -127.8% | at low | -121.6% | +30.2% | -120.9% | +17.3% |
| 5 y | 5-year | -127.8% | at low | -121.6% | +30.2% | -120.9% | +17.3% |
| alltime | all time | -127.8% | at low | -121.6% | +30.2% | -120.9% | +17.3% |
Moderna EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$3.76 B(+14.4%) | -$1.19 B(-1601.3%) | -$3.46 B(+73.3%) |
| Sep 2024 | - | $79.00 M(-106.4%) | -$2.00 B(-47.1%) |
| Jun 2024 | - | -$1.23 B(+9.7%) | -$3.78 B(-9.8%) |
| Mar 2024 | - | -$1.12 B(-504.0%) | -$4.19 B(+27.6%) |
| Dec 2023 | -$3.28 B(-133.0%) | $278.00 M(-116.4%) | -$3.28 B(+80.8%) |
| Sep 2023 | - | -$1.70 B(+3.3%) | -$1.82 B(-248.7%) |
| Jun 2023 | - | -$1.64 B(+654.1%) | $1.22 B(-77.5%) |
| Mar 2023 | - | -$218.00 M(-112.5%) | $5.42 B(-45.5%) |
| Dec 2022 | $9.95 B(-26.4%) | $1.75 B(+30.4%) | $9.95 B(-27.3%) |
| Sep 2022 | - | $1.34 B(-47.6%) | $13.69 B(-14.3%) |
| Jun 2022 | - | $2.56 B(-40.8%) | $15.98 B(-3.5%) |
| Mar 2022 | - | $4.31 B(-21.4%) | $16.56 B(+22.4%) |
| Dec 2021 | $13.53 B(-1948.1%) | $5.49 B(+51.3%) | $13.53 B(+74.5%) |
| Sep 2021 | - | $3.63 B(+15.6%) | $7.75 B(+98.5%) |
| Jun 2021 | - | $3.14 B(+145.5%) | $3.90 B(+489.9%) |
| Mar 2021 | - | $1.28 B(-542.2%) | $662.00 M(-190.4%) |
| Dec 2020 | -$732.00 M(+42.1%) | -$289.00 M(+30.8%) | -$732.00 M(+23.3%) |
| Sep 2020 | - | -$221.00 M(+108.5%) | -$593.74 M(+21.9%) |
| Jun 2020 | - | -$106.00 M(-8.6%) | -$487.23 M(-3.9%) |
| Mar 2020 | - | -$116.00 M(-23.0%) | -$507.25 M(-1.5%) |
| Dec 2019 | -$515.00 M(+44.5%) | -$150.74 M(+31.7%) | -$515.00 M(+3.7%) |
| Sep 2019 | - | -$114.48 M(-9.2%) | -$496.64 M(+9.3%) |
| Jun 2019 | - | -$126.02 M(+1.8%) | -$454.49 M(+10.0%) |
| Mar 2019 | - | -$123.75 M(-6.5%) | -$413.00 M(+15.9%) |
| Dec 2018 | -$356.45 M(+51.5%) | -$132.38 M(+83.0%) | -$356.45 M(+44.6%) |
| Sep 2018 | - | -$72.33 M(-14.4%) | -$246.49 M(+40.9%) |
| Jun 2018 | - | -$84.54 M(+25.8%) | -$174.98 M(+91.3%) |
| Mar 2018 | - | -$67.20 M(+199.7%) | -$91.49 M(+262.1%) |
| Dec 2017 | -$235.33 M(+12.8%) | -$22.42 M(+2618.4%) | -$25.27 M(+668.2%) |
| Sep 2017 | - | -$824.80 K(-21.4%) | -$3.29 M(+28.4%) |
| Jun 2017 | - | -$1.05 M(+8.0%) | -$2.56 M(+56.1%) |
| Mar 2017 | - | -$971.90 K(+119.2%) | -$1.64 M(+109.5%) |
| Dec 2016 | -$208.66 M(-6351.0%) | - | - |
| Dec 2016 | - | -$443.30 K(+353.7%) | -$783.60 K(-112.3%) |
| Sep 2016 | - | -$97.70 K(-23.9%) | $6.37 M(+17.2%) |
| Jun 2016 | - | -$128.40 K(+12.4%) | $5.43 M(+19.7%) |
| Mar 2016 | - | -$114.20 K(-101.7%) | $4.54 M(+36.0%) |
| Dec 2015 | $3.34 M(-161.0%) | $6.71 M(-749.9%) | $3.34 M(+37.2%) |
| Sep 2015 | - | -$1.03 M(+1.0%) | $2.43 M(-166.5%) |
| Jun 2015 | - | -$1.02 M(-22.3%) | -$3.66 M(-384.7%) |
| Mar 2015 | - | -$1.31 M(-122.7%) | $1.28 M(-123.5%) |
| Dec 2014 | -$5.47 M(+302.0%) | $5.80 M(-181.5%) | -$5.47 M(-58.6%) |
| Sep 2014 | - | -$7.12 M(-281.7%) | -$13.21 M(+88.7%) |
| Jun 2014 | - | $3.92 M(-148.6%) | -$7.00 M(-37.0%) |
| Mar 2014 | - | -$8.07 M(+316.0%) | -$11.11 M(+593.0%) |
| Dec 2013 | -$1.36 M(-81.2%) | -$1.94 M(+112.7%) | -$1.60 M(-63.8%) |
| Sep 2013 | - | -$912.00 K(+390.3%) | -$4.43 M(-9.7%) |
| Jun 2013 | - | -$186.00 K(-113.0%) | -$4.90 M(+131.4%) |
| Mar 2013 | - | $1.44 M(-130.1%) | -$2.12 M(-70.7%) |
| Dec 2012 | -$7.24 M(-73.2%) | -$4.76 M(+242.9%) | -$7.24 M(-61.7%) |
| Sep 2012 | - | -$1.39 M(-153.5%) | -$18.87 M(-12.5%) |
| Jun 2012 | - | $2.60 M(-170.6%) | -$21.57 M(-26.2%) |
| Mar 2012 | - | -$3.68 M(-77.5%) | -$29.21 M(-3.3%) |
| Dec 2011 | -$27.03 M(+15.8%) | -$16.40 M(+301.3%) | -$30.21 M(+66.8%) |
| Sep 2011 | - | -$4.09 M(-19.1%) | -$18.11 M(-16.3%) |
| Jun 2011 | - | -$5.05 M(+7.9%) | -$21.63 M(+9.5%) |
| Mar 2011 | - | -$4.68 M(+8.7%) | -$19.75 M(-4.2%) |
| Dec 2010 | -$23.35 M(+196.7%) | -$4.30 M(-43.4%) | -$20.61 M(+7.8%) |
| Sep 2010 | - | -$7.61 M(+140.2%) | -$19.12 M(+6.4%) |
| Jun 2010 | - | -$3.17 M(-42.8%) | -$17.96 M(-16.6%) |
| Mar 2010 | - | -$5.54 M(+97.2%) | -$21.55 M(+192.6%) |
| Dec 2009 | -$7.87 M | -$2.81 M(-56.5%) | -$7.37 M(-53.6%) |
| Sep 2009 | - | -$6.45 M(-4.4%) | -$15.87 M(-12.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2009 | - | -$6.75 M(-178.1%) | -$18.18 M(-25.6%) |
| Mar 2009 | - | $8.65 M(-176.5%) | -$24.44 M(-47.5%) |
| Dec 2008 | -$46.57 M(-7.1%) | -$11.31 M(+29.0%) | -$46.57 M(+0.3%) |
| Sep 2008 | - | -$8.77 M(-32.6%) | -$46.42 M(-13.2%) |
| Jun 2008 | - | -$13.01 M(-3.5%) | -$53.48 M(+2.1%) |
| Mar 2008 | - | -$13.48 M(+20.8%) | -$52.40 M(+4.5%) |
| Dec 2007 | -$50.14 M(+89.8%) | -$11.16 M(-29.4%) | -$50.14 M(+2.1%) |
| Sep 2007 | - | -$15.82 M(+32.5%) | -$49.13 M(+19.9%) |
| Jun 2007 | - | -$11.94 M(+6.4%) | -$40.96 M(+38.6%) |
| Mar 2007 | - | -$11.22 M(+10.5%) | -$29.55 M(+11.9%) |
| Dec 2006 | -$26.41 M(-17.4%) | -$10.15 M(+32.7%) | -$26.41 M(+4.8%) |
| Sep 2006 | - | -$7.65 M(+1354.6%) | -$25.20 M(-4.3%) |
| Jun 2006 | - | -$526.00 K(-93.5%) | -$26.33 M(-22.7%) |
| Mar 2006 | - | -$8.09 M(-9.6%) | -$34.06 M(+6.6%) |
| Dec 2005 | -$31.97 M(+18.2%) | -$8.94 M(+1.8%) | -$31.97 M(+11.8%) |
| Sep 2005 | - | -$8.78 M(+6.3%) | -$28.59 M(+6.0%) |
| Jun 2005 | - | -$8.26 M(+37.8%) | -$26.98 M(+4.9%) |
| Mar 2005 | - | -$5.99 M(+7.7%) | -$25.71 M(-4.9%) |
| Dec 2004 | -$27.05 M(+463.9%) | -$5.56 M(-22.4%) | -$27.05 M(-0.5%) |
| Sep 2004 | - | -$7.17 M(+2.5%) | -$27.19 M(+4.6%) |
| Jun 2004 | - | -$6.99 M(-4.5%) | -$25.99 M(+166.3%) |
| Mar 2004 | - | -$7.32 M(+28.5%) | -$9.76 M(+103.5%) |
| Dec 2003 | -$4.80 M(-58.6%) | -$5.70 M(-4.7%) | -$4.80 M(+30.6%) |
| Sep 2003 | - | -$5.98 M(-164.7%) | -$3.67 M(+356.7%) |
| Jun 2003 | - | $9.24 M(-491.6%) | -$804.00 K(-92.9%) |
| Mar 2003 | - | -$2.36 M(-48.4%) | -$11.26 M(-2.8%) |
| Dec 2002 | -$11.59 M(+33.1%) | -$4.57 M(+47.1%) | -$11.59 M(+17.1%) |
| Sep 2002 | - | -$3.11 M(+155.3%) | -$9.89 M(+16.9%) |
| Jun 2002 | - | -$1.22 M(-54.7%) | -$8.46 M(-8.0%) |
| Mar 2002 | - | -$2.69 M(-6.8%) | -$9.20 M(+5.7%) |
| Dec 2001 | -$8.71 M(-9.3%) | -$2.88 M(+71.5%) | -$8.71 M(-6.8%) |
| Sep 2001 | - | -$1.68 M(-13.9%) | -$9.34 M(+0.3%) |
| Jun 2001 | - | -$1.95 M(-10.9%) | -$9.31 M(-2.9%) |
| Mar 2001 | - | -$2.19 M(-37.7%) | -$9.60 M(-0.1%) |
| Dec 2000 | -$9.60 M(+6.1%) | -$3.52 M(+112.8%) | -$9.60 M(-3.4%) |
| Sep 2000 | - | -$1.65 M(-26.0%) | -$9.94 M(-2.1%) |
| Jun 2000 | - | -$2.23 M(+1.6%) | -$10.15 M(+6.7%) |
| Mar 2000 | - | -$2.20 M(-43.0%) | -$9.51 M(-1.1%) |
| Dec 1999 | -$9.05 M(+341.2%) | -$3.85 M(+106.9%) | -$9.62 M(+18.5%) |
| Sep 1999 | - | -$1.86 M(+16.4%) | -$8.11 M(+25.8%) |
| Jun 1999 | - | -$1.60 M(-30.4%) | -$6.45 M(+27.7%) |
| Mar 1999 | - | -$2.30 M(-2.2%) | -$5.05 M(+77.1%) |
| Dec 1998 | -$2.05 M(-64.0%) | -$2.35 M(+1076.0%) | -$2.85 M(+1.9%) |
| Sep 1998 | - | -$200.00 K(0.0%) | -$2.80 M(-33.3%) |
| Jun 1998 | - | -$200.00 K(+100.0%) | -$4.20 M(-20.8%) |
| Mar 1998 | - | -$100.00 K(-95.7%) | -$5.30 M(-10.2%) |
| Dec 1997 | -$5.70 M(+1040.0%) | -$2.30 M(+43.8%) | -$5.90 M(+63.9%) |
| Sep 1997 | - | -$1.60 M(+23.1%) | -$3.60 M(+80.0%) |
| Jun 1997 | - | -$1.30 M(+85.7%) | -$2.00 M(+300.0%) |
| Mar 1997 | - | -$700.00 K(<-9900.0%) | -$500.00 K(<-9900.0%) |
| Dec 1996 | -$500.00 K(<-9900.0%) | - | - |
| Sep 1996 | - | $0.00(-100.0%) | $0.00(-100.0%) |
| Jun 1996 | $0.00(-100.0%) | $200.00 K(+100.0%) | -$100.00 K(-66.7%) |
| Mar 1996 | - | $100.00 K(-133.3%) | -$300.00 K(-25.0%) |
| Dec 1995 | - | -$300.00 K(+200.0%) | -$400.00 K(+100.0%) |
| Sep 1995 | - | -$100.00 K(<-9900.0%) | -$200.00 K(<-9900.0%) |
| Jun 1995 | -$100.00 K(-150.0%) | $0.00(0.0%) | $0.00(-100.0%) |
| Mar 1995 | - | $0.00(-100.0%) | $100.00 K(>+9900.0%) |
| Dec 1994 | - | -$100.00 K(-200.0%) | $0.00(-100.0%) |
| Sep 1994 | - | $100.00 K(0.0%) | $200.00 K(0.0%) |
| Jun 1994 | $200.00 K | $100.00 K(-200.0%) | $200.00 K(+100.0%) |
| Mar 1994 | - | -$100.00 K(-200.0%) | $100.00 K(-50.0%) |
| Dec 1993 | - | $100.00 K(0.0%) | $200.00 K(+100.0%) |
| Sep 1993 | - | $100.00 K | $100.00 K |
FAQ
- What is Moderna annual EBITDA?
- What is the all time high annual EBITDA for Moderna?
- What is Moderna annual EBITDA year-on-year change?
- What is Moderna quarterly EBITDA?
- What is the all time high quarterly EBITDA for Moderna?
- What is Moderna quarterly EBITDA year-on-year change?
- What is Moderna TTM EBITDA?
- What is the all time high TTM EBITDA for Moderna?
- What is Moderna TTM EBITDA year-on-year change?
What is Moderna annual EBITDA?
The current annual EBITDA of MRNA is -$3.76 B
What is the all time high annual EBITDA for Moderna?
Moderna all-time high annual EBITDA is $13.53 B
What is Moderna annual EBITDA year-on-year change?
Over the past year, MRNA annual EBITDA has changed by -$473.00 M (-14.41%)
What is Moderna quarterly EBITDA?
The current quarterly EBITDA of MRNA is -$1.19 B
What is the all time high quarterly EBITDA for Moderna?
Moderna all-time high quarterly EBITDA is $5.49 B
What is Moderna quarterly EBITDA year-on-year change?
Over the past year, MRNA quarterly EBITDA has changed by -$1.46 B (-526.62%)
What is Moderna TTM EBITDA?
The current TTM EBITDA of MRNA is -$3.46 B
What is the all time high TTM EBITDA for Moderna?
Moderna all-time high TTM EBITDA is $16.56 B
What is Moderna TTM EBITDA year-on-year change?
Over the past year, MRNA TTM EBITDA has changed by -$179.00 M (-5.45%)